Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott(Institute of Cancer Research), Yung‐Jue Bang(Institute of Cancer Research), Dominique Berton-Rigaud(Institute of Cancer Research), Elena Élez(Institute of Cancer Research), Michael J. Pishvaian(Institute of Cancer Research), Hope S. Rugo(Institute of Cancer Research), Igor Puzanov(Institute of Cancer Research), Janice M. Mehnert(Institute of Cancer Research), Kyaw Aung(Institute of Cancer Research), Juanita Lopez(Institute of Cancer Research), Marion Carrigan(Institute of Cancer Research), Sanatan Saraf(Institute of Cancer Research), Mei Chen(Institute of Cancer Research), Jean‐Charles Soria(Institute of Cancer Research)
Cited by 45
Abstract
(Abstracted from J Clin Oncol 2017;35:2535–2541) Endometrial cancer (EC) identified at an early stage is successfully treated in a majority of patients with surgery with or without radiotherapy or chemotherapy. For patients with advanced disease, however, the prognosis is poor; 5-year survival rates are less than 50% in patients with lymph node metastases and less than 20% in those with peritoneal or distant metastases.
Related Papers
No related papers found
Powered by citation graph analysis